DOCSLIB.ORG

Oncological Drug Poster

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Oncological Drug Poster Oncological Drugs Created by the Njardarson Group (The University of Arizona): Edon Vitaku, Elizabeth A. Ilardi, Monica A. Fallon, Erik B. Gerlach, Jack Siqueiros, Jón T. Njarðarson Purinethol Methotrexate Myleran Leukeran Cytoxan Fluorouracil Oncovin Cosmegen Alkeran Velban Vercyte Thioguanine Imuran Cytosar-U Matulane Lysodren Megace Blenoxane Adriamycin RDF DTIC-Dome Amsacrine ( Mercaptopurine ) ( Methotrexate ) ( Busulfan ) ( Chlorambucil ) ( Cyclophosphamide ) ( Fluorouracil ) ( Vincristine ) ( Dactinomycin ) ( Melphalan ) ( Vinblastine ) ( Pipobroman ) ( Thioguanine ) ( Azathioprine ) ( Cytarabine ) ( Procarbazine ) ( Mitotane ) ( Megestrol ) ( Bleomycin ) ( Doxorubicin ) ( Dacarbazine ) ( Amsacrine ) NLY/CLE/BLE* BLE/BRE/HEA/NEC/TLY/NLY* MYELOID LEUKEMIA CLE/NLY/HLY/TES/OUT/RTU* BREAST CANCER COLORECTAL CANCER MULTIPLE MYELOMA TESTICULAR CANCER MULTIPLE MYELOMA HODGKIN LYMPHOMA BREAST CANCER MLE/NLE/ELE/BLE* GRAFT-VERSUS-HOST-DISEASE MLE/NLY* HODGKIN LYMPHOMA BRAIN TUMORS BRE/END* HODGKIN LYMPHOMA NLY/HLY/MLE/BRE/GAS/OVA/SCL/THY/BLA* MELANOMA LYMPHOBLASTIC LEUKEMIA Approved 1953 Approved 1953 Approved 1954 Approved 1957 Approved 1959 Approved 1962 Approved 1963 Approved 1964 Approved 1964 Approved 1965 Approved 1966 Approved 1966 Approved 1968 Approved 1969 Approved 1969 Approved 1970 Approved 1971 Approved 1973 Approved 1974 Approved 1975 Approved 1976 CeeNU BiCNU Nolvadex Platinol Cerubidine Cytadren Emcyt Mutamycin Zanosar Vindesine VePesid Novantrone Ifex Paraplatin Eulexin Hexalen Idamycin DES Fludara Nipent Masoprocol ( Lomustine ) ( Carmustine ) ( Tamoxifen ) ( Cisplatin ) ( Daunorubicin ) ( Aminoglutethimide ) ( Estramustine ) ( Mitomycin ) ( Streptozocin ) ( Vindesine ) ( Etoposide ) ( Mitoxantrone ) ( Ifosfamide ) ( Carboplatin ) ( Flutamide ) ( Altretamine ) ( Idarubicin ) ( Diethylstilbestrol ) ( Fludarabine ) ( Pentostatin ) ( Masoprocol ) HODGKIN LYMPHOMA BTU/MUM/NLY* BREAST CANCER TES/OVA* MLE/BLY* BREAST CANCER PROSTATE CANCER BLA/ALA/COL* HLY/PTU/CTU* HLY/MLE/MEL/BRE/NCL* SMALL CELL LUNG CANCER MLE/NLY/PRO/BRE* TESTICULAR CANCER OVARIAN CANCER PROSTATE CANCER OVARIAN CANCER MYELOID LEUKEMIA BRE/PRO* CLE/NLY* HAIRY CELL LEUKEMIA SKIN CANCER Approved 1976 Approved 1977 Approved 1977 Approved 1978 Approved 1979 Approved 1980 Approved 1981 Approved 1981 Approved 1982 Approved 1982 Approved 1983 Approved 1987 Approved 1988 Approved 1989 Approved 1989 Approved 1990 Approved 1990 Approved 1990s Approved 1991 Approved 1991 Approved 1992 Taxol Vumon Leustatin Prograf Ethyol Arimidex Casodex Intron A Photofrin Leukine Anexsia Taxotere Gemzar Zoladex Visipaque Camptosar Lupon Depot Kadian Nilandron Aredia Hycamtin ( Paclitaxel ) ( Teniposide ) ( Cladribine ) ( Tacrolimus ) ( Amifostine ) ( Anastrozole ) ( Bicalutamide ) ( Interferon Alfa-2b ) ( Porfimer ) ( Sargramostim ) ( Acetaminophen & Hydrocodone ) ( Docetaxel ) ( Gemcitabine ) ( Goserelin ) ( Iodixanol ) ( Irinotecan ) ( Leuprolide ) ( Morphine ) ( Nilutamide ) ( Pamidronate ) ( Topotecan ) BREAST CANCER CLE/SCL* NLY/CLE/HLE* GRAFT-VERSUS-HOST DISEASE CHEM. IND. NAUSEA & VOMITING BREAST CANCER PROSTATE CANCER MEL/HLE/HLY* ESOPHAGEAL CANCER MYELOID LEUKEMIA OPIOD ANALGESIC BREAST CANCER NCL/PAN* PROSTATE CANCER CONTRAST AGENT COLORECTAL CANCER PROSTATE CANCER OPIOD ANALGESIC PROSTATE CANCER HYPERCALCEMIA NON-SMALL CELL LUNG CARCIN Approved 1992 Approved 1992 Approved 1993 Approved 1994 Approved 1995 Approved 1995 Approved 1995 Approved 1995 Approved 1995 Approved 1995 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Agrylin Xibrom Anzemet Kytril Aldara Femara Neumega Rituxan Quadramet Fareston Proleukin Xeloda Celebrex Actiq Arava Zofran Prometrium Tomudex Thalomid Herceptin Valstar ( Anagrelide ) ( Bromfenac ) ( Dolasetron ) ( Granisetron ) ( Imiquimod ) ( Letrozole ) ( Oprelvekin ) ( Rituximab ) ( Samarium Sm 153 Lexidronam ) ( Toremifene ) ( Aldesleukin ) ( Capecitabine ) ( Celecoxib ) ( Fentanyl ) ( Leflunomide ) ( Ondansetron ) ( Progesterone ) ( Raltitrexed ) ( Thalidomide ) ( Trastuzumab ) ( Valrubicin ) MYELOID LEUKEMIA OPIOD ANALGESIC CHEM. IND. NAUSEA & VOMITING CHEM. IND. NAUSEA & VOMITING BASAL CELL CARCINOMA BREAST CANCER THROMBOCYTOPENIA NON HODGKIN LYMPHOMA BONE CANCER BREAST CANCER MEL/KID* BREAST CANCER OPIOID ANALGESIC OPIOID ANALGESIC MYELOID LEUKEMIA CHEM. IND. NAUSEA & VOMITING BREAST CANCER COLORECTAL CANCER MULTIPLE MYELOMA BREAST CANCER BLADDER CANCER Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1998 Approved 1998 Approved 1998 Approved 1998 Approved 1998 Approved 1998 Approved 1998 Approved 1998 Approved 1998 Approved 1998 Approved 1998 Alitretinoin Levulan Targretin Ellence Aromasin Uvadex Rapamune Temodar Navelbine Trisenox Mylotarg Trelstar Depot Campath Gleevec Zometa Faslodex Zevalin Eloxatin Eloxatin Neulasta SecreFlo ( Alitretinoin ) ( Aminolevulinic Acid ) ( Bexarotene ) ( Epirubicin ) ( Exemestane ) ( Methoxsalen ) ( Sirolimus ) ( Temozolomide ) ( Vinorelbine ) ( Arsenic Trioxide ) ( Gemtuzumab Ozogamicin ) ( Triptorelin ) ( Alemtuzumab ) ( Imatinib ) ( Zoledronic Acid ) ( Fulvestrant ) ( Ibritumomab Tiuxetan ) ( Oxaliplatin ) ( Oxaliplatin, 5-Fluorouracil, & Leucovorin ) ( Pegfilgrastim ) ( Secretin ) SKIN CANCER SKIN CANCER TLY/BRE/SKI* BREAST CANCER BREAST CANCER T-CELL LYMPHOMA GRAFT-VERSUS-HOST DISEASE BRAIN TUMORS NCL/BRE* MYELOID LEUKEMIA MYELOID LEUKEMIA PROSTATE CANCER LYMPHOCYTIC LEUKEMIA MLE/GTU* MULTIPLE MYELOMA BREAST CANCER NON HODGKIN LYMPHOMA COLORECTAL CANCER COLORECTAL CANCER LEUKOCYTE GROWTH FACTOR PANCREATIC CANCER Approved 1999 Approved 1999 Approved 1999 Approved 1999 Approved 1999 Approved 1999 Approved 1999 Approved 1999 Approved 1999 Approved 2000 Approved 2000 Approved 2000 Approved 2001 Approved 2001 Approved 2001 Approved 2002 Approved 2002 Approved 2002 Approved 2002 Approved 2002 Approved 2002 Plenaxis UroXatral Emend Velcade Premarin Iressa Aloxi Bexxar Avastin Erbitux Sensipar Clolar Tarceva Metvixia Myfortic Kepivance Alimta Arranon Nexavar Sprycel Vectibix ( Abarelix ) ( Alfuzosin ) ( Aprepitant ) ( Bortezomib ) ( Conjugated Estrogens ) ( Gefitinib ) ( Palonosetron ) ( Tositumomab ) ( Bevacizumab ) ( Cetuximab ) ( Cinacalcet ) ( Clofarabine ) ( Erlotinib ) ( Methyl Aminolevulinate ) ( Mycophenolic Acid ) ( Palifermin ) ( Pemetrexed ) ( Nelarabine ) ( Sorafenib ) ( Dasatinib ) ( Panitumumab ) PROSTATE CANCER PROSTATE CANCER CHEM. IND. NAUSEA & VOMITING MUM/MLY* BREAST CANCER NON-SMALL CELL LUNG CARCIN CHEM. IND. NAUSEA & VOMITING NON HODGKIN LYMPHOMA COL/NCL/BRE/BTU/KID/OVA* COLORECTAL CANCER PARATHYROID CARCINOMA LYMPHOBLASTIC LEUKEMIA PANCREATIC CANCER SKIN CANCER GRAFT-VERSUS HOST DISEASE BLO/BMA* NCL/MES* BLE/BLY* KIDNEY CANCER MLE/BLE* COLORECTAL CANCER Approved 2003 Approved 2003 Approved 2003 Approved 2003 Approved 2003 Approved 2003 Approved 2003 Approved 2003 Approved 2004 Approved 2004 Approved 2004 Approved 2004 Approved 2004 Approved 2004 Approved 2004 Approved 2004 Approved 2004 Approved 2005 Approved 2005 Approved 2006 Approved 2006 Oncaspar Gardasil Sutent Zolinza Ixempra Tykerb Tasigna Evista Torisel Treanda Degarelix Fusilev Mozobil Nplate Afinitor Arzerra Votrient Folotyn Elitek Istodax Jevtana ( Pegaspargase ) ( Quadrivalent Human Papillomavirus Vaccine ) ( Sunitinib ) ( Vorinostat ) ( Ixabepilone ) ( Lapatinib ) ( Nilotinib ) ( Raloxifene ) ( Temsirolimus ) ( Bendamustine ) ( Degarelix ) ( Folinic Acid ) ( Plerixafor ) ( Romiplostim ) ( Everolimus ) ( Ofatumumab ) ( Pazopanib ) ( Pralatrexate ) ( Rasburicase ) ( Romidepsin ) ( Cabazitaxel ) CLE/NLY/BLY/MLE* CER/ANA* KIDNEY CANCER T-CELL LYMPHOMA BREAST CANCER BREAST CANCER MYELOID LEUKEMIA BREAST CANCER KIDNEY CANCER LYMPHOCYTIC LEUKEMIA PROSTATE CANCER BONE CANCER MULTIPLE MYELOMA THROMBOCYTOPENIA KID/PAN/BRE* LYMPHOCYTIC LEUKEMIA OVARIAN CANCER T-CELL LYMPHOMA TUMOR LYSIS SYNDROME T-CELL LYMPHOMA PROSTATE CANCER Approved 2006 Approved 2006 Approved 2006 Approved 2006 Approved 2007 Approved 2007 Approved 2007 Approved 2007 Approved 2007 Approved 2008 Approved 2008 Approved 2008 Approved 2008 Approved 2008 Approved 2009 Approved 2009 Approved 2009 Approved 2009 Approved 2009 Approved 2009 Approved 2010 Xgeva Halaven Provenge Zytiga Erwinaze Adcretris Xalkori Yervoy Sylatron Jakafi Vandetanib Zelboraf Inlyta Bosulif Cometriq Kyprolis Xtandi Voraxaze Picato Synribo Perjeta ( Denosumab ) ( Eribulin ) ( Sipuleucel-T ) ( Abiraterone ) ( Asparaginase Erwinia Chrysanthemi ) ( Brentuximab Vedotin ) ( Crizotinib ) ( Ipilimumab ) ( Peginterferon Alfa-2b ) ( Ruxolitinib ) ( Vandetanib ) ( Vemurafenib ) ( Axitinib ) ( Bosutinib ) ( Cabozantinib ) ( Carfilzomib ) ( Enzalutamide ) ( Glucarpidase ) ( Ingenol Mebutate ) ( Omacetaxine ) ( Pertuzumab ) MULTIPLE MYELOMA BREAST CANCER PROSTATE CANCER PROSTATE CANCER LYMPHOBLASTIC LEUKEMIA HODGKIN LYMPHOMA NON-SMALL CELL LUNG CARCIN MELANOMA MELANOMA BONE MARROW CANCER THYROID CANCER MELANOMA KIDNEY CANCER MYELOID LEUKEMIA THYROID CANCER MULTIPLE MYELOMA PROSTATE CANCER KIDNEY CANCER SKIN CANCER MYELOID LEUKEMIA BREAST CANCER Approved 2010 Approved 2010 Approved 2010 Approved 2011 Approved 2011 Approved 2011 Approved 2011 Approved 2011 Approved 2011 Approved 2011 Approved 2011 Approved 2011 Approved 2012 Approved 2012 Approved 2012 Approved 2012 Approved 2012 Approved 2012 Approved 2012 Approved 2012 Approved 2012 Iclusig Stivarga Neutroval Erivedge BEP BEACOPP CAPOX CHOP CMF CVP
Load more

Recommended publications
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Photodynamic Therapy with Methyl Aminolevulinate for Primary Nodular Basal Cell Carcinoma: Results of Two Randomized Studies
    Clinical trial Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies Peter Foley, MBBS, BMedSc, MD, FACD, Michael Freeman, MBBS, FACD, Alan Menter, MB, FAAD, Gregory Siller, MBBS, FACD, Rokea A. El-Azhary, MD, PhD, FAAD, Kurt Gebauer, MBBS, FACD, Nicholas J. Lowe, MD, FAAD, Michael T. Jarratt, MD, FAAD, Dedee F. Murrell, BMBCh, MD, FAAD, Phoebe Rich, MD, FAAD, David M. Pariser, MD, FAAD, Allan R. Oseroff, MD, PhD, FAAD, Ross Barnetson, MD, FRACP, FACD, Christopher Anderson, MBBS, FACD, Steven Kossard, MBBS, FACD, Lawrence E. Gibson, MD, FAAD, and Whitney D. Tope, MPhIL, MD, FAAD From the Department of Medicine Abstract (Dermatology), The University of Background Data suggest that photodynamic therapy using topical methyl aminolevulinate Melbourne, St. Vincent’s Hospital (MAL PDT) may be a noninvasive alternative to excisional surgery for nodular basal cell Melbourne, Fitzroy, Vic., Suite 5 ACH carcinoma (BCC). In the studies described here, we investigated the histologic response, House, Benowa and Department of Dermatology, Princess Alexandra tolerability, and cosmetic outcome with MAL PDT for primary nodular BCC (£ 5 mm in depth). Hospital, Woolloongabba, Qld, Fremantle Methods Two multicenter, randomized, double-blind studies with similar design and Dermatology, Fremantle, WA, and procedures were conducted. After surface debridement and minor tumor debulking, MAL cream Department of Dermatology, St. George 160 mg/g (66 patients with 75 lesions) or placebo cream (65 patients with 75 lesions) was applied Hospital, University of New South Wales, for 3 h, followed by illumination with broad-spectrum red light (75 J/cm2, 570–670 nm).
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • And Grand Overview
    Welcome and Grand Overview Rose Aurigemma, PhD Acting Associate Director, Developmental Therapeutics Program Division of Cancer Treatment & Diagnosis, NCI July 23, 2021 Thank You to the Organizing Committee Weiwei Chen, Program Director, PTGB, DTP Rachelle Salomon, Program Director, BRB, DTP Sharad Verma, Program Director, PTGB, DTP Jason Yovandich, Chief, BRB, DTP Sundar Venkatachalam, Chief, PTGB, DTP 2 Introduction to the Developmental Therapeutics Program In 1955, congress created the Cancer Chemotherapy National Service Center which evolved, both structurally and functionally, into today’s Developmental Therapeutics Program (DTP). DTP’s involvement in the discovery or development of many anticancer therapeutics on the market today demonstrates its indelible impact on efforts to improve the health and well-being of people with cancer. 3 Approved Cancer Therapies with DTP Assistance 2018 Moxetumomab pasudotox-tdfk 1983 Etoposide (NSC 141540) 2015 Dinutuximab (Unituxin, NSC 764038) 1982 Streptozotocin (NSC 85998) Ecteinascidin 743 (NSC 648766) 1979 Daunorubicin (NSC 82151) 2012 Omacetaxine (homoharringtonine, NSC 141633) 1978 Cisplatin (cis-platinum) (NSC 119875) 2010 Eribulin (NSC 707389) 1977 Carmustine (BCNU) (NSC 409962) Sipuleucel-T (NSC 720270) 1976 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosurea (CCNU) 2009 Romidepsin (NSC 630176) (NSC 9037) Pralatrexate (NSC 713204) 1975 Dacarbazine (NSC 45388) 2004 Azacitidine (NSC 102816) 1974 Doxorubicin (NSC 123127) Cetuximab (NSC 632307) Mitomycin C (NSC 26980) 2003 Bortezomib (NSC 681239) 1973
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • BC Cancer Benefit Drug List September 2021
    Page 1 of 65 BC Cancer Benefit Drug List September 2021 DEFINITIONS Class I Reimbursed for active cancer or approved treatment or approved indication only. Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to Restricted Funding (R) provide the appropriate clinical information for each patient. NOTES 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated. 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified. 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or [email protected] DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Therapy for Metastatic Castration-Sensitive Prostate Cancer using abiraterone tablet Genitourinary UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer abiraterone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone acitretin capsule Lymphoma reversal of early dysplastic and neoplastic stem changes LYNOS I first-line treatment of epidermal
    [Show full text]
  • Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia
    Published OnlineFirst September 20, 2013; DOI: 10.1158/2159-8290.CD-13-0350 RESEARCH ARTICLE Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia Tea Pemovska 1 , Mika Kontro 2 , Bhagwan Yadav 1 , Henrik Edgren 1 , Samuli Eldfors1 , Agnieszka Szwajda 1 , Henrikki Almusa 1 , Maxim M. Bespalov 1 , Pekka Ellonen 1 , Erkki Elonen 2 , Bjørn T. Gjertsen5 , 6 , Riikka Karjalainen 1 , Evgeny Kulesskiy 1 , Sonja Lagström 1 , Anna Lehto 1 , Maija Lepistö1 , Tuija Lundán 3 , Muntasir Mamun Majumder 1 , Jesus M. Lopez Marti 1 , Pirkko Mattila 1 , Astrid Murumägi 1 , Satu Mustjoki 2 , Aino Palva 1 , Alun Parsons 1 , Tero Pirttinen 4 , Maria E. Rämet 4 , Minna Suvela 1 , Laura Turunen 1 , Imre Västrik 1 , Maija Wolf 1 , Jonathan Knowles 1 , Tero Aittokallio 1 , Caroline A. Heckman 1 , Kimmo Porkka 2 , Olli Kallioniemi 1 , and Krister Wennerberg 1 ABSTRACT We present an individualized systems medicine (ISM) approach to optimize cancer drug therapies one patient at a time. ISM is based on (i) molecular profi ling and ex vivo drug sensitivity and resistance testing (DSRT) of patients’ cancer cells to 187 oncology drugs, (ii) clinical implementation of therapies predicted to be effective, and (iii) studying consecutive samples from the treated patients to understand the basis of resistance. Here, application of ISM to 28 samples from patients with acute myeloid leukemia (AML) uncovered fi ve major taxonomic drug-response sub- types based on DSRT profi les, some with distinct genomic features (e.g., MLL gene fusions in subgroup IV and FLT3 -ITD mutations in subgroup V). Therapy based on DSRT resulted in several clinical responses.
    [Show full text]
  • Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy with Hospitalization for Upper Gastrointestinal Tract Bleeding
    Supplementary Online Content Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. doi:10.1001/jama.2018.17242 eAppendix. PPI Co-therapy and Anticoagulant-Related UGI Bleeds This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Appendix: PPI Co-therapy and Anticoagulant-Related UGI Bleeds Table 1A Exclusions: end-stage renal disease Diagnosis or procedure code for dialysis or end-stage renal disease outside of the hospital 28521 – anemia in ckd 5855 – Stage V , ckd 5856 – end stage renal disease V451 – Renal dialysis status V560 – Extracorporeal dialysis V561 – fitting & adjustment of extracorporeal dialysis catheter 99673 – complications due to renal dialysis CPT-4 Procedure Codes 36825 arteriovenous fistula autogenous gr 36830 creation of arteriovenous fistula; 36831 thrombectomy, arteriovenous fistula without revision, autogenous or 36832 revision of an arteriovenous fistula, with or without thrombectomy, 36833 revision, arteriovenous fistula; with thrombectomy, autogenous or nonaut 36834 plastic repair of arteriovenous aneurysm (separate procedure) 36835 insertion of thomas shunt 36838 distal revascularization & interval ligation, upper extremity 36840 insertion mandril 36845 anastomosis mandril 36860 cannula declotting; 36861 cannula declotting; 36870 thrombectomy, percutaneous, arteriovenous
    [Show full text]
  • Aminolevulinic Acid (ALA) As a Prodrug in Photodynamic Therapy of Cancer
    Molecules 2011, 16, 4140-4164; doi:10.3390/molecules16054140 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Review Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer Małgorzata Wachowska 1, Angelika Muchowicz 1, Małgorzata Firczuk 1, Magdalena Gabrysiak 1, Magdalena Winiarska 1, Małgorzata Wańczyk 1, Kamil Bojarczuk 1 and Jakub Golab 1,2,* 1 Department of Immunology, Centre of Biostructure Research, Medical University of Warsaw, Banacha 1A F Building, 02-097 Warsaw, Poland 2 Department III, Institute of Physical Chemistry, Polish Academy of Sciences, 01-224 Warsaw, Poland * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel. +48-22-5992199; Fax: +48-22-5992194. Received: 3 February 2011 / Accepted: 3 May 2011 / Published: 19 May 2011 Abstract: Aminolevulinic acid (ALA) is an endogenous metabolite normally formed in the mitochondria from succinyl-CoA and glycine. Conjugation of eight ALA molecules yields protoporphyrin IX (PpIX) and finally leads to formation of heme. Conversion of PpIX to its downstream substrates requires the activity of a rate-limiting enzyme ferrochelatase. When ALA is administered externally the abundantly produced PpIX cannot be quickly converted to its final product - heme by ferrochelatase and therefore accumulates within cells. Since PpIX is a potent photosensitizer this metabolic pathway can be exploited in photodynamic therapy (PDT). This is an already approved therapeutic strategy making ALA one of the most successful prodrugs used in cancer treatment. Key words: 5-aminolevulinic acid; photodynamic therapy; cancer; laser; singlet oxygen 1. Introduction Photodynamic therapy (PDT) is a minimally invasive therapeutic modality used in the management of various cancerous and pre-malignant diseases.
    [Show full text]
  • Oregon Health Authority Division of Medical Assistance Programs Addendum a - Final OPPS Apcs for CY 2012 Effective October 1, 2012
    Oregon Health Authority Division of Medical Assistance Programs Addendum A - Final OPPS APCs for CY 2012 Effective October 1, 2012 Relative APC Group Title SI Weight 0001 Level I Photochemotherapy S 0.5042 0002 Fine Needle Biopsy/Aspiration T 1.6115 0003 Bone Marrow Biopsy/Aspiration T 3.5702 0004 Level I Needle Biopsy/ Aspiration Except Bone Marrow T 4.5746 0005 Level II Needle Biopsy/Aspiration Except Bone Marrow T 8.1566 0006 Level I Incision & Drainage T 1.4206 0007 Level II Incision & Drainage T 13.1250 0008 Level III Incision and Drainage T 20.5648 0012 Level I Debridement & Destruction T 0.3878 0013 Level II Debridement & Destruction T 0.8785 0015 Level III Debridement & Destruction T 1.4989 0016 Level IV Debridement & Destruction T 2.7592 0017 Level V Debridement & Destruction T 21.6661 0019 Level I Excision/ Biopsy T 4.4238 0020 Level II Excision/ Biopsy T 8.2746 0021 Level III Excision/ Biopsy T 17.0074 0022 Level IV Excision/ Biopsy T 23.2662 0028 Level I Breast Surgery T 25.5054 0029 Level II Breast Surgery T 33.4070 0030 Level III Breast Surgery T 44.8999 0031 Smoking Cessation Services X 0.2997 0034 Mental Health Services Composite S 2.7295 0035 Vascular Puncture and Minor Diagnostic Procedures X 0.2691 0037 Level IV Needle Biopsy/Aspiration Except Bone Marrow T 15.3499 0039 Level I Implantation of Neurostimulator Generator S 216.7598 0040 Level I Implantation/Revision/Replacement of Neurostimulator Electrodes S 63.7616 0041 Level I Arthroscopy T 29.6568 0042 Level II Arthroscopy T 57.0137 0045 Bone/Joint Manipulation Under
    [Show full text]
  • Pub 100-04 Medicare Claims Processing
    Department of Health CMS Manual System & Human Services (DHHS) Pub 100-04 Medicare Claims Centers for Medicare Processing & Medicaid Services (CMS) Transmittal 2128 Date: DECEMBER 29, 2010 Change Request 7275 SUBJECT: January 2011 Update of the Ambulatory Surgical Center (ASC) Payment System I. SUMMARY OF CHANGES: This Recurring Update Notification describes changes to and billing instructions for various payment policies implemented in the January 2011 ASC update. As appropriate, this notification also includes updates to the Healthcare Common Procedure Coding System (HCPCS). EFFECTIVE DATE: January 1, 2011 IMPLEMENTATION DATE: January 3, 2011 Disclaimer for manual changes only: The revision date and transmittal number apply only to red italicized material. Any other material was previously published and remains unchanged. However, if this revision contains a table of contents, you will receive the new/revised information only, and not the entire table of contents. II. CHANGES IN MANUAL INSTRUCTIONS: (N/A if manual is not updated) R=REVISED, N=NEW, D=DELETED-Only One Per Row. R/N/D CHAPTER / SECTION / SUBSECTION / TITLE N/A III. FUNDING: For Fiscal Intermediaries (FIs), Regional Home Health Intermediaries (RHHIs): No additional funding will be provided by CMS; Contractor activities are to be carried out within their operating budgets. For Medicare Administrative Contractors (MACs): The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer.
    [Show full text]
  • APPENDICES: a Systematic Review of Photodynamic Therapy in the Treatment of Pre-Cancerous Skin Conditions, Barrett's Oesophagu
    Health Technology Assessment 2010; Vol. 14: No.371 Health Technology Assessment 2010; Vol. 14: No. 37 Appendix 5 Pre-cancerous skin scoping Appendix 6 Appendices Go to main text Skin cancer scoping Appendix 7 Barrett’s oesophagus scoping Appendix 8 Oesophageal cancer scoping A systematic review of photodynamic Appendix 9 therapy in the treatment of pre- Lung cancer scoping cancerous skin conditions, Barrett’s Appendix 10 oesophagus and cancers of the biliary Biliary tract cancer scoping Appendix 11 tract, brain, head and neck, lung, Brain cancer scoping oesophagus and skin Appendix 12 Head and neck cancer scoping D Fayter, M Corbett, M Heirs, D Fox Appendix 13 and A Eastwood Actinic keratosis data extraction Appendix 14 Bowen’s disease data extraction Appendix 15 Basal cell carcinoma data extraction Appendix 16 Barrett’s oesophagus data extraction Appendix 17 Oesophageal cancer data extraction Appendix 18 Lung cancer data extraction Appendix 19 Biliary tract cancer data extraction Appendix 20 Brain cancer data extraction Appendix 21 July 2010 Head and neck cancer data extraction 10.3310/hta14370 Health Technology Assessment NIHR HTA programme www.hta.ac.uk HTA How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below). Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.
    [Show full text]